Sanbio Group, of Tokyo, and Hitachi Chemical Co. Ltd., of Tokyo, said they have executed an agreement with Hitachi Chemical Advanced Therapeutics Solutions LLC, Hitachi Chemical's U.S. subsidiary that engages in contract manufacturing and development of regenerative medicine products, to manufacture Sanbio's SB-623 regenerative medicine candidate for central nervous system disorders.